Knocking down TNFR2 on cancer cells by CRISPR/Cas9 technology significantly impaired the growth of colon cancer, and increased the number of tumor-infiltrating IFN-γ+ CD8 cells (Li et al., 2023). This evidence concerns the gene TNFRSF1B and malignant colon neoplasm.